GMED Quote, Financials, Valuation and Earnings

Intuitive Surgical, Inc. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 28.31%. Globus Medical, Inc.'s return on equity of 10.08% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Globus Medical, Inc. has a consensus price target of $95.70, signalling upside risk potential of 8.97%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $596.36 which suggests that it could grow by 7.28%. Given that Globus Medical, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Globus Medical, Inc. is more attractive than Intuitive Surgical, Inc..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Globus Medical, Inc.'s net income of $119M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.38x while Intuitive Surgical, Inc.'s PE ratio is 73.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.37x versus 21.03x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 26.1%. Globus Medical, Inc.'s return on equity of 10.08% beat ResMed, Inc.'s return on equity of 25.6%.

Globus Medical, Inc. has a consensus price target of $95.70, signalling upside risk potential of 8.97%. On the other hand ResMed, Inc. has an analysts' consensus of $293.47 which suggests that it could grow by 16.69%. Given that ResMed, Inc. has higher upside potential than Globus Medical, Inc., analysts believe ResMed, Inc. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. Globus Medical, Inc.'s net income of $119M is lower than ResMed, Inc.'s net income of $348.5M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.38x while ResMed, Inc.'s PE ratio is 25.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.37x versus 7.06x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solventum Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 60.4%. Globus Medical, Inc.'s return on equity of 10.08% beat Solventum Corp.'s return on equity of 42.2%.

Globus Medical, Inc. has a consensus price target of $95.70, signalling upside risk potential of 8.97%. On the other hand Solventum Corp. has an analysts' consensus of $84.36 which suggests that it could grow by 3.01%. Given that Globus Medical, Inc. has higher upside potential than Solventum Corp., analysts believe Globus Medical, Inc. is more attractive than Solventum Corp..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Solventum Corp. quarterly revenues of $2.1B. Globus Medical, Inc.'s net income of $119M is lower than Solventum Corp.'s net income of $1.3B. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.38x while Solventum Corp.'s PE ratio is 9.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.37x versus 1.70x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 14.18%. Globus Medical, Inc.'s return on equity of 10.08% beat Stryker Corp.'s return on equity of 14.06%.

Globus Medical, Inc. has a consensus price target of $95.70, signalling upside risk potential of 8.97%. On the other hand Stryker Corp. has an analysts' consensus of $429.31 which suggests that it could grow by 21.34%. Given that Stryker Corp. has higher upside potential than Globus Medical, Inc., analysts believe Stryker Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Globus Medical, Inc.'s net income of $119M is lower than Stryker Corp.'s net income of $859M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.38x while Stryker Corp.'s PE ratio is 46.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.37x versus 5.61x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.